|
 |
FlolanThis page contains recent news articles, when available, and an overview of Flolan but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.Treprostinil was approved for intravenous use in 2004 based on comparisons with the standard IV prostanoid drug epoprostenol (Flolan), ... MedPage Today 'What gives them the right to put a price on my life?' - Oct 30, 2009 When she was diagnosed, Dr. Davis saw what he describes as a "dramatic improvement" in her condition when she began taking Flolan, the popular PAH drug that ... Globe and Mail Study Finds Life-Threatening Risks from Medication Errors in Hospitals ... - Nov 4, 2009 ...medication errors for patients infused with epoprostenol (Flolan®) and treprostinil (Remodulin®) and provided guidelines to help reduce these risks. ... Reuters Funding for rare-disease therapy under the microscope - Nov 2, 2009 ...the expensive intravenous drug Flolan, would be cut off if she continued to accept a free secondary drug given to her on a compassionate basis by the ... Globe and Mail GSK va a poner en marcha un innovador estudio en hipertensión arterial ... - Nov 12, 2009 A finales de los 90, el tratamiento intravenoso de GlaxoSmithKline para la HAP, Flolan ® (epoprostenol), fue el primer medicamento autorizado para el ... acceso.com (Comunicado de prensa) Gilead Buying Myogen | Biotech | Financial Articles & Investing News... - Oct 2, 2006 Denver-based Myogen currently markets and distributes Flolan (epoprostenol ... Flolan was approved in 1995 and is indicated for the long-term intravenous ... TheStreet.com - TheStreet.com (subscription) Myogen Signs Marketing Deal With Glaxo - Mar 6, 2006 ..."The Flolan distribution agreement is expected to underwrite the development of our own ... Flolan, the oldest PAH drug, must be taken intravenously. ... TheStreet.com - TheStreet.com (subscription) CHEST: Viagra Efficacy for PAH Sparks Debate - Nov 4, 2005 He said he's mainly concerned that IV Flolan might be withheld, in favor of Viagra, ... Dr. Shapiro said that there are two issues concerning IV Flolan ... MedPage Today Myogen Loss Narrows - Aug 7, 2006 ..."With the launch of Flolan commercial operations and with our PAH-focused sales force now fully engaged, we have taken an important step forward in our ... TheStreet.com - TheStreet.com (subscription) Gilead buying hypertension drug from Navitas - May 29, 2008 The company's current hypertension drugs include Flolan and Letairis, though the Foster City, Calif.-based company is better known for its HIV treatments ... Boston Globe Teva Pharmaceutical (TEVA) Receives FDA Approval for Generic Flolan - Apr 28, 2008 Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced that the US Food and Drug Administration has granted approval for the Company's Abbreviated New ... StreetInsider.com - StreetInsider.com (subscription) Accredo wins distribution contract for drug used to treat lung... - Apr 18, 2006 Flolan is marketed by Myogen Inc., a private company headquartered in the ... Flolan degrades rapidly and must be given through a constant IV for life; ... Bizjournals.com Competition looms for Silver Spring drugmaker - Dec 14, 2005 ...''In terms of convenience and safety alone we are now beating Flolan,â€? Hadeed said. ... Flolan must be administered continually, directly into an artery, ... Business Gazette … SIGNS 5-YEAR SPECIALTY PHARMACY PACT FOR FLOLAN. - Jun 1, 2006 Accredo Health Group, Inc., Memphis, Tenn., the nation's largest specialty pharmacy operation, has signed an exclusive five-year agreement as the sole ... Entrepreneur Filtered Pump Sets and Flolan (Epoprostenol) Interruption - Oct 27, 2005 Epoprostenol (FLOLAN) is an intravenous medication used to treat primary pulmonary hypertension (PPH), a condition characterized by progressive increases in ... Medscape FDA Approves Teva's Generic Flolan for Injection - Apr 30, 2008 The FDA cleared Teva Pharmaceutical Industries' ANDA to market epoprostenol, the first generic version of GlaxoSmithKline's Flolan for injection. ... FDA news - FDA news (subscription) United Therapeutics Guidance Announcement - Part 2. - Feb 26, 2007 And she does have a number of friends who are on Flolan, Remodulin and what have you. And she pointed out that looking at things as a patient the ... Free with registration - America's Intelligence Wire - AccessMyLibrary.com Event Brief of Q4 2006 United Therapeutics Earnings Conference Call -... - Feb 20, 2007 Also, whether or not the strength this quarter was coming more from new patient starts, or if we're seeing this also from Flolan transition patients. ... Free with registration - Fair Disclosure Wire - AccessMyLibrary.com Q4 2005 Myogen Earnings Conference Call - Part 2. - Mar 6, 2006 LUCY LU: And then just a couple quick questions on Flolan. ... I was curious, in terms of Flolan, Flolan has significant price disparity from its nearest ... Free with registration - America's Intelligence Wire - AccessMyLibrary.com Pulmonary Hypertension: Surviving an incurable disease - May 1, 2005 ...either with the initial dyspnea before diagnosis or because of accidental disconnection from a drug called epoprostenol (Flolan), one lifeline for PAH. ... ModernMedicine … PHARMACY PACT FOR FLOLAN. - Biotech Business | HighBeam … - Jun 1, 2006 ACCREDO SIGNS 5-YEAR SPECIALTY PHARMACY PACT FOR FLOLAN. ... find Biotech Business articles. Accredo Health Group, Inc., Memphis, Tenn., the nation's ... Pay-Per-View - Biotech Business - HighBeam Research An entrepreneur starts a biotech to save her daughter's life - Jun.... - Jun 25, 2007 Unstable at room temperature, Flolan requires patients to carry an ice pack 24 ... Her first step was to develop a drug that lasted longer than Flolan. ... CNNMoney.com United Therapeutics' Remodulin Study OK'D - Mar 21, 2006 This study confirms the clinical benefit of Remodulin in pulmonary arterial hypertension patients, provides expanded labeling specific to Flolan transition, ... RedOrbit United Thera: EU MRP ends for Remodulin.(United Therapeutics Corp.)( … - Aug 22, 2005 Interim analysis of the Phase IV trial revealed that 13 of 14 patients (93%) taking Remodulin were able to successfully transfer from Flolan treatment and ... $4.95 - Pharma Marketletter - ECNext Business Update; Accredo Health signs pharmacy agreement for Flolan - May 18, 2006 2006 MAY 18 - (NewsRx.com) -- Accredo Health Group, Inc., announced an exclusive 5-year agreement as the sole specialty pharmacy for Flolan (epoprostenol ... Pay-Per-View - Biotech Business Week - Factiva, from Dow Jones FDA Approves United Therapeutics' Remodulin Label Expansion - Mar 23, 2006 The phase IV study, which was successfully completed last year, involved the transition of patients from GlaxoSmithKline's Flolan to either Remodulin or ... RedOrbit Myogen Reports Positive Top Line Results for Second Ambrisentan … - Apr 10, 2006 Flolan was approved by the FDA in 1995 and is indicated for the long-term intravenous treatment of primary pulmonary hypertension and pulmonary hypertension ... Free with registration - Business Wire - AccessMyLibrary.com Pulmonary Hypertension: Surviving an incurable disease - May 1, 2005 Epoprostenol (Flolan). When Ruth was diagnosed with NYHA Functional Class ... Flolan is not compatible with other drugs, and the chances of a bolus being ... ModernMedicine Gilead gets early end to waiting period for Myogen purchase - Oct 27, 2006 The company also markets and distributes Flolan in the United States through an agreement ... Flolan was approved in 1995 and is indicated for the long-term ... San Jose Business Journal - San Jose Business Journal (subscription) GlaxoSmithKline and Myogen sign ambrisentan licensing deal and Flolan... - Mar 13, 2006 In related news, the two firms say they have entered into a second agreement covering the distribution of GSK's Flolan (epoprostenol sodium), ... $4.95 - Pharma Marketletter - ECNext Scripps, UCSD hit with fines for errors - May 22, 2008 UCSD Medical Center received its penalty for a July incident in which hospital staff improperly administered Flolan, a drug for people with pulmonary ... San Diego Union - Tribune - San Diego Union Tribune Rare Lung Disorder Requires High-Touch SP Service Model - Aug 1, 2005 PPPY costs for Flolan could range from $70000 to $120000 (depending on the titration), Remodulin around $100000 and Ventavis anywhere from $50000 to $80000 ... Pay-Per-View - Specialty Pharmacy News - Factiva, from Dow Jones Darusentan Data to Be Presented at ISH 2006 -- Fukuoka, Japan - Oct 17, 2006 Myogen and GlaxoSmithKline have entered into a global PAH collaboration in which Myogen has marketing and distribution rights to GlaxoSmithKline's Flolan(R) ... Genetic Engineering News - Genetic Engineering News (press release) Isabelle Cormier vit d'espoir - Feb 13, 2007 Le Flolan doit lui être injecté directement dans les veines 24 heures sur ... Le traitement au Flolan coûte 9 000 $ par mois. «Heureusement, que c'est mon ... La Nouvelle/L'Union Teva получила разрешение FDA на маркетинг дженерика препарата … - Apr 30, 2008 ИзраильÑ?каÑ? компаниÑ? Teva Pharmaceutical Industries получила разрешение УправлениÑ? по контролю за качеÑ?твом продуктов и медикаментов СШÐ? (FDA) на маркетинг ... ФармацевтичеÑ?кий веÑ?тник United Therapeutics Profit Nearly Triples, to $12.2 Million | Article... - Aug 3, 2005 While it must be constantly pumped into the body, it doesn't have to be frozen and carried in a special backpack, as Glaxo's drug Flolan does. ... Pay-Per-View - Washington Post - HighBeam Research MedImmune Inc. One MedImmune ... - May 1, 2006 While Remodulin must constantly be pumped into the body, it doesn't have to be frozen and carried in a special backpack, as Glaxo's drug Flolan does. ... Pay-Per-View - Washington Post - ProQuest Archiver Loislaw Federal District Court Opinions - NOIA v. DIVISION 1181 ATU —... - Sep 14, 2007 Id. To treat his IPAH, Noia receives a drug named Flolan through an implanted ... Noia suffers vasculitis as an allergic side effect to Flolan, however, ... Pay-Per-View - Loislaw Federal District Court Opinions - Loislaw Myogen Reports 2006 Second Quarter Results - Dec 31, 2006 With the launch of Flolan commercial operations and with our PAH-focused ... Meanwhile, the Flolan distribution agreement is expected to underwrite the ... businesswire.com United Therapeutics Profit Nearly Triples, to $12.2 Million - Aug 3, 2005 While it must be constantly pumped into the body, it doesn't have to be frozen and carried in a special backpack, as Glaxo's drug Flolan does. ... Washington Post United Therapeutics Leads the Charge - Sep 21, 2005 Remodulin is a so-called prostacyclin analog, like Flolan, but it's much ... It comes as a ready-to-use solution and, as opposed to Flolan, is stable at ... TheStreet.com - TheStreet.com (subscription) United Therapeutics foresees solid growth - Dec 9, 2005 ...''In terms of convenience and safety alone we are now beating Flolan,â€? Hadeed said. ... Flolan must be administered continually, directly into an artery, ... Business Gazette Q2 2006 Myogen Earnings Conference Call - Part 1. - Aug 7, 2006 Myogen recognizes Flolan revenue net of both supply price to GSK and the ... Flolan net sales for the quarter ended June 30, 2006 were $1.6 million on gross ... Free with registration - America's Intelligence Wire - AccessMyLibrary.com New Option for Rare Condition - Jun 19, 2007 The first drug approved for the condition in 1995 was GSK's Flolan, ... Gilead now sells Flolan in the US, while GSK markets it outside the US. ... Subscription - Wall Street Journal Online - Dow Jones & Company Gilead Sciences at Thomas Weisel 2007 Healthcare Conference - Final. - Sep 5, 2007 Flolan is an agreement that was brought from the Myogen deal to promote Flolan for a three-year period here in the US. This is the type of slide that makes ... Free with registration - Fair Disclosure Wire - AccessMyLibrary.com Living in the shadow of death An Aberdeen sheriff tells Stephen... - May 6, 2008 Warner was put onto a drug called Flolan, one of a class of drugs known as ... This is expected to be much cheaper than Flolan, made by pharmaceuticals ... Pay-Per-View - The Herald - ProQuest Archiver Gilead Sciences at CIBC World Markets Annual Biotechnology & … - Apr 12, 2007 And then at the bottom of the slide, I just wanted to briefly mention Flolan. Flolan is a product that was a part of the Myogen portfolio. ... Free with registration - Fair Disclosure Wire - AccessMyLibrary.com Gilead compra Myogen en 2.500 millones - Oct 2, 2006 Myogen desarrolla varios medicamentos para el tratamiento de afecciones circulatorias pulmonares y cardÃacas, al tiempo que su medicamento Flolan para la ... elEconomista.es Merger and Acquisition Scenario - Aug 2, 2008 Darusentan; Letairis (Ambrisentan); Flolan (Epoprostenol Sodium) ... Flolan (Epoprostenol Sodium). Digestive System. Liver Disorders. Hepatitis. $250.00 - Revere Reports - Revere Press Release: United Therapeutics Announces FDA Approval of … - Mar 21, 2006 The Phase 4 study, which was successfully completed last year, involved the transition of patients from Flolan to either Remodulin or placebo. ... Pay-Per-View - PR Newswire - HighBeam Research Merger and Acquisition Scenario - Jan 26, 2008 Buyer (Total: 21). Darusentan; Letairis (Ambrisentan); Flolan (Epoprostenol Sodium); Hepsera (Adefovir Dipivoxil). Target (Total: 14) ... $250.00 - Revere Reports - Revere TECHNOLOGY Sinclair Extends D ... - Mar 2, 2007 United Therapeutics' lung-disorder drug, Remodulin, was linked to a higher rate of bloodstream infections than Flolan, a similar therapy made by ... Pay-Per-View - Washington Post - ProQuest Archiver Merger and Acquisition Scenario - Mar 22, 2008 Buyer (Total: 22). Darusentan; Letairis (Ambrisentan); Flolan (Epoprostenol Sodium); Viread (Tenofovir Disoproxil Fumarate) ... $250.00 - Revere Reports - Revere PAH: Market ripe for expansion as big pharma interest increases. - Mar 21, 2006 Despite being considered the gold standard for treating more severe cases of PAH, GSKs Flolan has come under increased commercial competition, ... Free with registration - M2 Presswire - AccessMyLibrary.com Merger and Acquisition Scenario - Nov 22, 2008 Darusentan; Letairis (Ambrisentan); Flolan (Epoprostenol Sodium) ... Flolan (Epoprostenol Sodium). Digestive System. Liver Disorders. Hepatitis. Hepatitis B ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Apr 7, 2007 Darusentan; Ambrisentan; Flolan (Epoprostenol Sodium); Viread (Tenofovir Disoproxil ... Flolan (Epoprostenol Sodium). Digestive System. Liver Disorders ... $250.00 - Revere Reports - Revere New PH Therapy Gets FDA Nod - Feb 3, 2005 Two current therapies for PH, Flolan (a synthetic prostacyclin) and Remodulin (a prostacyclin analog), are delivered either through a surgically-placed ... PH Neighborhood Merger and Acquisition Scenario - Nov 29, 2008 Darusentan; Letairis (Ambrisentan); Flolan (Epoprostenol Sodium) ... Flolan (Epoprostenol Sodium). Digestive System. Liver Disorders. Hepatitis. Hepatitis B ... $250.00 - Revere Reports - Revere Drug/Medical Device Report Cotherix, Inc (CTRX) - Jan 6, 2007 Gilead Sciences, Inc. (GILD) / Myogen Flolan (Epoprostenol. Sodium) ... GlaxoSmithKline plc (ADR) (GSK) / Flolan (Epoprostenol. Sodium) ... $70.00 - Revere Reports - Revere Merger and Acquisition Scenario - Dec 27, 2008 Darusentan; Letairis (Ambrisentan); Flolan (Epoprostenol Sodium) ... Flolan (Epoprostenol Sodium). Digestive System. Liver Disorders. Hepatitis. Hepatitis B ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - May 19, 2007 Buyer (Total: 19). Darusentan; Ambrisentan; Flolan (Epoprostenol Sodium); Viread (Tenofovir Disoproxil Fumarate). Target (Total: 38) ... $250.00 - Revere Reports - Revere United Therapeutics Corp., Silver Spring, MD, April 13 (DDMAC).(HUMAN... - May 1, 2005 Further, the booklet compared Remodulin to Flolan, another drug indicated for intravenous treatment of pulmonary hypertension. ... $4.95 - Warning Letter Bulletin - ECNext Merger and Acquisition Scenario - Mar 8, 2008 Buyer (Total: 22). Darusentan; Letairis (Ambrisentan); Flolan (Epoprostenol Sodium); Viread (Tenofovir Disoproxil Fumarate) ... $250.00 - Revere Reports - Revere Myogen Filing Shows Some Fancy Footwork - Mar 20, 2006 The company also received an older PAH drug from GlaxoSmithKline, known as Flolan, that will lose its patent protection in the first half of this year. ... TheStreet.com - TheStreet.com (subscription) Netherlands Corporate News - Gilead Sciences neemt Myogen over voor … - Feb 10, 2006 Myogen currently markets and distributes Flolan(R) (epoprostenol sodium) in the United ... Flolan was approved in 1995 and is indicated for the long-term ... Netherlands Corporate News - Netherlands Corporate News (persbericht) Myogen plans to seek drug approval - Apr 10, 2006 Myogen licensed the right from GlaxoSmithKline to distribute Flolan in the United ... The FDA approved Flolan in 1995. Myogen said it doesn't expect to make ... Denver Business Journal Merger and Acquisition Scenario - Jan 26, 2008 Darusentan; Letairis (Ambrisentan); Flolan (Epoprostenol Sodium) ... Flolan (Epoprostenol Sodium). Digestive System. Liver Disorders. Hepatitis. Hepatitis B ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Dec 13, 2008 Buyer (Total: 22). Darusentan; Letairis (Ambrisentan); Flolan (Epoprostenol Sodium); Viread (Tenofovir Disoproxil Fumarate) ... $250.00 - Revere Reports - Revere … Signs Exclusive Five-year Specialty Pharmacy Agreement for Flolan.... - Apr 17, 2006 Accredo Health Signs Exclusive Five-year Specialty Pharmacy Agreement for Flolan. from PR Newswire. Highbeam Research – FREE Trial. Pay-Per-View - PR Newswire - HighBeam Research Merger and Acquisition Scenario - Jun 21, 2008 Buyer (Total: 22). Darusentan; Letairis (Ambrisentan); Flolan (Epoprostenol Sodium); Viread (Tenofovir Disoproxil Fumarate) ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Jul 12, 2008 Darusentan; Letairis (Ambrisentan); Flolan (Epoprostenol Sodium) ... Flolan (Epoprostenol Sodium). Digestive System. Liver Disorders. Hepatitis. $250.00 - Revere Reports - Revere Press Release: A Drug That Improves Exercise Capacity by a Greater … - Jul 22, 2008 Although surveyed pulmonologists indicated that Gleevec's efficacy will be similar to, not greater than that of Flolan, Gleevec's safety measures and ... Pay-Per-View - PR Newswire - HighBeam Research Myogen drug sales reach $1.6M in Q2 - Aug 7, 2006 The Westminster company (NASDAQ: MYOG) said Monday it expected sales of Flolan to fall between $3.75 million and $4.5 million for the year. ... Bizjournals.com Hope for a cure: Pulmonary arterial hypertension (PAH) - Dec 11, 2006 Not very many people are on this combo of medications, I believe I was the first in BC to add Viagra to Flolan...talk about feeling like the experimental ... CTV.ca Gilead Sciences at Wachovia Securities CEO Summit - Final. - Jun 26, 2007 Hepsera, our product for hepatitis B, and then you can see the two products that we actually have for pulmonary arterial hypertension, Letairis and Flolan. ... Free with registration - Fair Disclosure Wire - AccessMyLibrary.com Myogen drug gets push Firm's hypertension medicine receives fast... - Mar 10, 2006 Flolan also treats pulmonary arterial hypertension. Read all of this article with a FREE trial. COPYRIGHT 2006 Rocky Mountain News. All rights reserved. ... Pay-Per-View - Rocky Mountain News - HighBeam Research Myogen drug gets push - Firm's hypertension medicine receives fast... - Mar 10, 2006 Flolan also treats pulmonary arterial hypertension. ... Flolan is the gold standard of care for very sick patients with the lung disease. ... $2.95 - Rocky Mountain News - NewsBank Building A Case for Medication Reconciliation - May 27, 2005 A newly admitted patient with pulmonary hypertension had been receiving FLOLAN (epoprostenol) IV at home at 2.4 mL/hour. The physician prescribed Flolan at ... Medscape MEDICATION ERRORS- IS COMMUNICATION THE KEY TO … - Jun 14, 2005 A newly admitted patient with pulmonary hypertension had been receiving FLOLAN (epoprostenol) IV at home at 2.4 mL/hour. The physician prescribed Flolan at ... Diabetes In Control Drug Combo Relieves Symptoms in Pulmonary Hypertension - Oct 20, 2008 Note that this study suggests that a combination of two drugs used to treat the condition -- sildenafil (Revatio) and epoprostenol (Flolan) -- work better ... MedPage Today Event Brief of Q3 2006 United Therapeutics Earnings Conference Call -... - Oct 31, 2006 But I would hasten to add you're supposed to be careful with Flolan as well. CHRIS DEMATROPOLIS: That's helpful; and then just 1 last question for Roger; ... Free with registration - Fair Disclosure Wire - AccessMyLibrary.com Myogen offers revenue predictions - May 8, 2006 The company's first product, Flolan, hit the market in the second quarter. The drug is intended to treat pulmonary arterial hypertension. ... Denver Business Journal Breathless - Health News - redOrbit - Jan 18, 2006 Many of these drugs, starting with GlaxoSmithkline's Flolan, introduced in 1995, are variants of prostacyclin, a naturally occurring fat molecule that ... RedOrbit Transplant patients can wait lifetime for donor - Aug 25, 2006 Clapham lives in San Diego and has Flolan, a drug used to treat primary pulmonary ... However, once he receives a transplant he no longer has to use Flolan. ... Nevada Appeal Connections: Alliances, JVs, M&A and the people behind them - Oct 15, 2005 When a patient with pulmonary hypertension begins intravenous treatment with the drug Flolan, even a brief interruption of the drug therapy can prove deadly ... Daily Deal - The Daily Deal Event Brief of Q3 2006 United Therapeutics Earnings Conference Call -... - Oct 3, 2006 But I would hasten to add you're supposed to be careful with Flolan as well. CHRIS DEMATROPOLIS: That's helpful; and then just 1 last question for Roger; ... Free with registration - America's Intelligence Wire - AccessMyLibrary.com Merger and Acquisition Scenario - Jun 16, 2007 Darusentan; Ambrisentan; Flolan (Epoprostenol Sodium); Viread (Tenofovir Disoproxil ... Vistide (cidofovir injection) and Flolan (epoprostenol sodium). ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Jan 27, 2007 Myogen Flolan (Epoprostenol Sodium). Dermatology. Research/Preclinical Stage Products. Therapeutics that are being investigated for the treatment of skin ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Sep 13, 2008 Buyer (Total: 22). Darusentan; Letairis (Ambrisentan); Flolan (Epoprostenol Sodium); Viread (Tenofovir Disoproxil Fumarate) ... $250.00 - Revere Reports - Revere United Therapuetics Draws Warning Letter for Remodulin Promotions - Apr 19, 2005 Specifically, the materials suggested that Flolan patients can successfully switch to Remodulin, but DDMAC said there is no clinical evidence indicating ... Pay-Per-View - Drug Industry Daily - Factiva, from Dow Jones Merger and Acquisition Scenario - Apr 5, 2008 Target (Total: 22). Darusentan; Letairis (Ambrisentan); Flolan (Epoprostenol Sodium); Viread (Tenofovir Disoproxil Fumarate) ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - May 17, 2008 Buyer (Total: 22). Darusentan; Letairis (Ambrisentan); Flolan (Epoprostenol Sodium); Viread (Tenofovir Disoproxil Fumarate) ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Dec 20, 2008 Buyer (Total: 22). Darusentan; Letairis (Ambrisentan); Flolan (Epoprostenol Sodium); Viread (Tenofovir Disoproxil Fumarate) ... $250.00 - Revere Reports - Revere Press Release: United Therapeutics Completes European Mutual … - Aug 10, 2005 ..."Refilings in Ireland, Spain and the United Kingdom will be bolstered by interim data from the United States Phase IV Flolan(R) transition trial. ... Pay-Per-View - PR Newswire - HighBeam Research Merger and Acquisition Scenario - Sep 13, 2008 Target (Total: 22). Darusentan; Letairis (Ambrisentan); Flolan (Epoprostenol Sodium); Viread (Tenofovir Disoproxil Fumarate) ... $250.00 - Revere Reports - Revere United Therapeutics Completes European Mutual Recognition for … - Aug 10, 2005 ..."Refilings in Ireland, Spain and the United Kingdom will be bolstered by interim data from the United States Phase IV Flolan(R) transition trial. ... $4.95 - PR Newswire - ECNext FDA Warns United Therapeutics Over Remodulin Promotions - Apr 27, 2005 Specifically, the materials suggested that Flolan patients can successfully switch to Remodulin, but DDMAC said there is no clinical evidence indicating ... Pay-Per-View - FDAnews Drug Daily Bulletin - Factiva, from Dow Jones Ventavis Launch to Expand Market for PAH Drugs; Accredo and Priority... - Apr 1, 2005 Both Flolan and Remodulin are continuously infused products, which "is inconvenient, but typically only the most severe patients go on one of the two" drugs ... Pay-Per-View - Specialty Pharmacy News - Factiva, from Dow Jones Competitors by Product Report - Sep 30, 2006 Products:. Flolan (Epoprostenol Sodium). Cotherix, Inc (CTRX) Products: ... GlaxoSmithKline plc (ADR) (GSK) Products:. Flolan (Epoprostenol Sodium) ... $75.00 - Revere Reports - Revere Merger and Acquisition Scenario - Nov 1, 2008 Buyer (Total: 22). Darusentan; Letairis (Ambrisentan); Flolan (Epoprostenol Sodium); Viread (Tenofovir Disoproxil Fumarate) ... $250.00 - Revere Reports - Revere Actelion to Get High Price On Japan Sales of Tracleer - Jun 9, 2005 ..."It seems that Japan's authorities also considered the price of Flolan when they set Tracleer's price," said Denise Anderson, an analyst in Zurich at ... Subscription - Wall Street Journal Online - Dow Jones & Company FINAL TRANSCRIPT - May 21, 2008 Flolan on behalf of GSK. Now have Letairis approved in the United States and are making great ... I mentioned the GSK and Gilead partnered on Flolan. ... $54.00 - Thomson StreetEvents - Alacra Store Serious patient errors at California hospitals disclosed in state... - Jun 30, 2008 UC San Diego officials said they have since held repeat drills with medical staff who treat patients who need Flolan and examined every step in the process. ... Los Angeles Times Today's Early Winners and Losers - Mar 7, 2006 In turn, Myogen will be responsible for the marketing and distribution of GlaxoSmithKline's Flolan in the United States. Shares of Myogen fell $4.47 to ... TheStreet.com - TheStreet.com (subscription) Volibris® (Ambrisentan) de GlaxoSmithKline recibe la Opinión Positiva... - Feb 26, 2008 GSK también comercializa Flolan, que está indicado para pacientes con HAP más severa. La opinión positiva se alcanzó después de que el CHMP revisara datos ... acceso.com |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines The Cancer News Network
COPYRIGHT 2009 CANCERNEWSNETWORK | Privacy |